Cancer and Peripheral Deep Vein Thrombosis are Both Independent Diseases Causes, Pathogenesis, Conclusions

2020 ◽  
Vol 2 (1) ◽  
pp. 1-3
Author(s):  
Drozdova Elena Viktorovna ◽  
Keyword(s):  
Deep Vein Thrombosis ◽  
World Health Organization ◽  
Cause Of Death ◽  
Controlled Trial ◽  
World Health ◽  
Peripheral Vein ◽  
Vein Thrombosis ◽  
Sickness Rate ◽  
Health Organization ◽  
Deep Vein

There is an undisputed thesis: CANCER has an often COMPLICATION such as DEEP VEIN THROMBOSIS. Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018. (according to World Health Organization). Sickness rate of deep vein thrombosis is approximately 100 per 100 000 population annually. Sickness rate of cancer in different countries is approximately 130-500 per 100 000 population annually. Thus, if deep vein thrombosis is considered to be a complication of cancer we must identify both these diseases simultaneously with frequency of 20 -76.9% The Research Objective To determine whether peripheral vein thromboses are the complications of cancer. The Method of the Research Randomized prospective parallel controlled trial.

scholarly journals COVID-19 Presented With Deep Vein Thrombosis: An Unusual Presenting

2020 ◽  
Vol 8 ◽  
pp. 232470962093123
Author(s):  
Lotfollah Davoodi ◽  
Hamed Jafarpour ◽  
Morteza Taghavi ◽  
Alireza Razavi
Keyword(s):  
Deep Vein Thrombosis ◽  
Color Doppler ◽  
Ground Glass Opacity ◽  
Color Doppler Ultrasound ◽  
World Health ◽  
Ground Glass ◽  
Vein Thrombosis ◽  
Chest X Ray ◽  
Health Organization ◽  
Deep Vein

On December 31, 2019, the World Health Organization was informed of a cluster of cases of pneumonia of unknown cause detected in Wuhan City, Hubei Province, China. The pneumonia was caused by a virus called SARS-Cov-2 (severe acute respiratory syndrome coronavirus 2), which was later named coronavirus infectious disease 2019 (COVID-19). The symptoms most commonly reported by patients affected by COVID-19 include fever, dry cough, and shortness of breath. In this report, we present a case of a 57-year-old woman who presented to the clinic’s infectious department with swelling, pain, warmth, and redness in the left leg who was treated with therapeutic heparin. There were no typical and distinguished symptoms of COVID-19, and she had no risk factor for deep vein thrombosis. Then chest X-ray revealed bilateral patchy ground-glass opacity, and computed tomography angiography was performed to rule out pulmonary thromboembolism, which showed no evidence of thrombosis. Left lower limb venous color Doppler ultrasound revealed dilatation and thrombosis in the external iliac and left iliac veins up to the level of the bifurcation of the common iliac veins, as well as thrombosis to the superficial and small saphenous veins. Because of ground-glass opacity and lymphopenia, nasal swabs were used for sampling, and SARS-CoV-2 nucleic acid was detected by reverse transcription polymerase chain reaction (RT-PCR). This case aims to arouse the medical staff’s awareness of deep vein thrombosis as a clinical symptom of COVID-19 even if the patient has no typical symptoms of COVID-19.

Controlled Trial of the Sequential Use of Streptokinase and Ancrod in the Treatment of Deep Vein Thrombosis of Lower Limb

1977 ◽  
Vol 37 (02) ◽  
pp. 222-232 ◽  
Author(s):  
D. A Tibbutt ◽  
C. N Chesterman ◽  
E. W Williams ◽  
T Faulkner ◽  
A. A Sharp
Keyword(s):  
Deep Vein Thrombosis ◽  
Clinical Improvement ◽  
Anticoagulant Therapy ◽  
Lower Limb ◽  
Oral Anticoagulant ◽  
Controlled Trial ◽  
Oral Anticoagulant Therapy ◽  
Control Group ◽  
Vein Thrombosis ◽  
Deep Vein

SummaryTreatment with streptokinase (‘Kabikinase’) was given to 26 patients with venographically confirmed deep vein thrombosis extending into the popliteal vein or above. Treatment was continued for 4 days and the patients were allocated randomly to oral anticoagulant therapy or a course of treatment with ancrod (‘Arvin’) for 6 days followed by oral anticoagulant therapy. The degree of thrombolysis as judged by further venographic examination at 10 days was not significantly different between the 2 groups. The majority of patients showed clinical improvement but there was no appreciable difference between the groups at 3 and 6 months. Haemorrhagic complications were a more serious problem during the period of treatment with ancrod than during the equivalent period in the control group.

Trial of Aspirin and RA 233 in Prevention of Post-operative Deep Vein Thrombosis

1973 ◽  
Vol 30 (01) ◽  
pp. 018-024 ◽  
Author(s):  
Edward H. Wood ◽  
Colin R.M. Prentice ◽  
D. Angus McGrouther ◽  
John Sinclair ◽  
George P. McNicol
Keyword(s):  
Deep Vein Thrombosis ◽  
Controlled Trial ◽  
Oral Anticoagulants ◽  
Antithrombotic Agent ◽  
Fractured Neck Of Femur ◽  
Neck Of Femur ◽  
Vein Thrombosis ◽  
Effective Prophylaxis ◽  
Deep Vein ◽  
Calf Vein

SummaryAlthough the oral anticoagulants provide effective prophylaxis against postoperative deep vein thrombosis following fracture of neck of femur there is a need for an antithrombotic agent which needs less laboratory control and does not cause haemorrhagic complications. It has been suggested that drugs causing inhibition of platelet function may fulfil these requirements. A controlled trial was carried out in which aspirin, RA 233, or a combination of these drugs was compared with a placebo in the prevention of post-operative deep vein thrombosis. In thirty patients undergoing surgery for fractured neck of femur the incidence of post-operative calf vein thrombosis, as detected by 125I-fibrinogen scanning, was not significantly different between the untreated and treated groups.

Diagnosis of deep-vein thrombosis: Adherence to guidelines and outcomes in real-world health care

2009 ◽  
Vol 102 (12) ◽  
pp. 1234-1240 ◽  
Author(s):  
Horst Gerlach ◽  
Viola Hach-Wunderle ◽  
Eberhard Rabe ◽  
Hanno Riess ◽  
Heike Carnarius ◽  
...  
Keyword(s):  
Health Care ◽  
Deep Vein Thrombosis ◽  
Ambulatory Care ◽  
Real World ◽  
Diagnostic Methods ◽  
World Health ◽  
Vein Thrombosis ◽  
Deep Vein ◽  
Work Up ◽  
Current Guidelines

SummaryCurrent guidelines recommend optimised algorithms for diagnosis of suspected deep-vein thrombosis (DVT). There is little data to determine to what extent real-world health care adheres to guidelines, and which outcome in terms of diagnostic efficiency and safety is achieved. This registry involved patients with clinically suspected DVT of the leg recruited in German ambulatory care between October and December 2005. Registry items were: diagnostic methods applied; diagnostic categories at day 1; and venous thromboembolic events up to 90 days in patients without firmly established DVT. A total of 4,976 patients were recruited in 326 centres. Venous ultrasonography was performed in 4,770 patients (96%), D-dimer assay in 1,773 patients (36%) and venography in 288 patients (6%). At day 1, DVT was confirmed in 1,388 patients (28%), and ruled out in 3,389 patients (68%), and work-up was inconclusive in 199 patients (4%).The rate of venous thromboembolism at 90 days was 0.34% (95% confidence interval [CI]: 0.09 to 0.88) in patients in whom the diagnosis of DVT had been ruled out, and 2.50% (95% CI: 0.69 to 6.28) in patients with inconclusive diagnostic workup. This nationwide evaluation in German ambulatory care revealed that the diagnostic work-up for suspected DVT did not adhere to current guidelines. However, the overall diagnostic safety was excellent, although there is potential for improvement in a well defined minority of patients.The TULIPA registry was funded by GlaxoSmithKline GmbH und Co KG, Munich.

Healthwise, Part 3. The importance of remaining active

2021 ◽  
Vol 15 (8) ◽  
pp. 384-391
Author(s):  
Linda Nazarko
Keyword(s):  
World Health Organization ◽  
Cause Of Death ◽  
Physical Inactivity ◽  
World Health ◽  
Activity Levels ◽  
The Third ◽  
Health Organization ◽  
The Uk

The old adage, ‘sitting will be the death of you’, is proving to be a grim prediction that is borne out by research. Globally, physical inactivity leads to approximately 5 million deaths per year and is the fourth leading cause of death and disability ( Kohl et al, 2012 ; World Health Organization (WHO), 2020 ). Evidence suggests that, in the UK, inactivity leads to around 69 000 preventable deaths annually ( Heron et al, 2019 ). This article, the third in a series, explores inactivity, its consequences and how readers can remain healthy and well by maintaining or increasing activity levels.

Sign in / Sign up

Export Citation Format

Share Document